查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1473724

谵妄市场预测：~2030 年

Delirium Market Research Report Forecast till 2030
出版日期: | 出版商: Market Research Future | 英文 132 Pages | 订单完成后即时交付

价格

在预测期内，Delirium 市场规模预计将以 5.84% 的复合年增长率成长。

人口老化的加剧、识别和诊断的改进以及技术的进步正在推动市场成长。

人口老化是谵妄市场的主要驱动力。 随着世界人口老化，谵妄的盛行率不断增加。 由于潜在疾病、认知障碍、多重用药和住院等因素，老年人更容易出现谵妄。 与年龄相关的生理变化，例如神经传导物质的变化和认知储备的减少，也会导致谵妄的脆弱性。

人口老化也影响创新研究工作，重点在于阐明谵妄的潜在机制和製定适合年龄的干预措施。 它还强调了跨学科合作和培训的重要性，以使医疗保健专业人员具备有效管理老年人谵妄症所需的知识和技能。 因此，老年人口的增加是谵妄市场扩大和发展的驱动力。

由于人口老化和慢性病增加，北美谵妄市场在 2022 年显示出最大的市场占有率。 该地区成熟的医疗基础设施和先进的医学研究正在促进谵妄管理诊断和治疗创新的发展。

欧洲谵妄市场预计将占据第二大市场。 依国家划分，德国预计将占最大占有率，法国预计在欧洲成长最快。

本报告调查了全球谵妄市场，并提供了市场定义和概述、市场成长影响因素和市场机会分析、市场规模趋势和预测、各个细分市场和地区的细分以及竞争对手，我们总结了环境、概况。

目录

第一章执行手册

第二章市场概述

第三章研究方法

第 4 章市场动态

  • 成长参数映射：促进因素
    • 老年人口增加
    • 改善识别和诊断
    • 对先进技术治疗的需求不断增加
  • 作业
    • 治疗费用飙升
    • 对资料安全和严格监管合规性的威胁
  • 机会
    • 与製药公司和学术机构的合作

第五章市场因素分析

  • 价值链分析
  • 波特五力分析
  • 新冠肺炎 (COVID-19) 影响分析

第 6 章全球谵妄市场：依类型

  • 过动症
  • 活动减退
  • 混合物

第 7 章全球谵妄市场：依诊断与治疗划分

  • 诊断
    • 临床检查
    • 身体检查
    • 影像检查
  • 处理中
    • 抗精神病药
    • 支持性护理

第 8 章全球谵妄市场：依最终用户划分

  • 医院
  • 特殊护理
  • 研究中心

第 9 章全球谵妄市场：依地区

  • 北美
  • 欧洲
  • 亚太地区
  • 其他领域

第10章竞争态势

  • 竞争对手仪表板
  • 公司市占率分析
  • 市场颠覆者与创新者
  • 市场领导者的招募策略
  • 竞争基准测试
  • 开发专案数量最多的公司
  • 主要公司名单：依地区划分
  • 公司股票
  • 主要公司的财务比较分析
  • 主要发展/成长策略

第十一章公司简介

  • OTSUKA PHARMACEUTICAL CO., LTD
  • MYLAN N.V
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
  • ZYDUS GROUP
  • GLENMARK PHARMACEUTICALS LTD
  • PFIZER
  • MYLAN N.V
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
  • GLENMARK PHARMACEUTICALS LTD
  • NOVARTIS AG

第12章建议/专家意见

第 13 章 MRFR 内容与团队

Product Code: MRFR/Pharma/4394-CR

Market Overview

The Delirium Market is anticipated to register a CAGR of 5.84% during the review period. Developing maturing populace, further developed distinguishing proof and finding, and mechanical headways are driving the market development.

The maturing populace is a critical driver of the delirium market. As the worldwide populace encounters a segment shift towards more seasoned grown-ups, the pervasiveness of delirium increments. More seasoned people are more powerless to delirium because of variables, for example, hidden medical issue, mental debilitations, polypharmacy, and hospitalization. The physiological changes related with maturing, like modifications in synapses and diminished mental save, additionally add to the weakness to delirium. The maturing populace's effect on the delirium market is complex. Right off the bat, it prompts a more prominent number of delirium cases, provoking a higher interest for indicative instruments, mediations, and the executives' procedures.

Furthermore, the maturing populace impacts innovative work endeavors zeroed in on figuring out the fundamental systems of delirium and creating age-explicit mediations. It additionally highlights the significance of interdisciplinary joint effort and preparing to furnish medical care experts with the information and abilities fundamental for successful delirium the board in more seasoned grown-ups. In general, the developing maturing populace is a main thrust behind the extension and progression of the delirium market.

Market Segmentation

Based on kind, the Delirium Market is divided into three segments: Hyperactive, Hypoactive, and Mixed.

The segmentation of the delirium market is predicated on diagnosis and therapy, which comprises both diagnosis and treatment.

The market is divided into hospitals, specialty care, and research centers based on the end-user.

The North American Delirium market addressed the greatest market share in 2022 considering developing people and a rising in continuous disorders, there is an extended knowledge of delirium as a fundamental piece of patient thought. The region's well established clinical benefits establishment and high-level clinical assessment add to the improvement of expressive and medicinal progressions in delirium the board.

Europe Delirium market should address the second-greatest market share in light of the extraordinary prosperity courses of action and example towards organizing prosperity organizations, including directing.

The Asia-Pacific clinical consideration directing market should create at the speediest rate from 2023 to 2030. This is a direct result of the rising spending in clinical benefits, quickly creating clinical consideration establishment, creating care with respect to Delirium, and creating people in the region.

The Rest of the World integrates the Middle East, Africa, and Latin America. The chief variables affecting the advancement of Delirium are in the Middle East and Africa.

Key Market Players

The key market players are Mylan N.V (US), Otsuka Pharmaceutical Co., Ltd (Japan), Mylan N.V (US), Teva Pharmaceutical Industries Ltd (Israel), Glenmark Pharmaceuticals Ltd (India), Zydus Group (India), Pfizer (India), Teva Pharmaceutical Industries Ltd (Israel), and Novartis AG (Switzerland).

TABLE OF CONTENTS

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS

1. EXECUTIVE'S HANDBOOK

  • 1.1. THE TOP PERFORMING SEGMENTS
  • 1.2. KEY TRENDS SUMMARIZED
  • 1.3. PRICING OUTLOOK
  • 1.4. STRATEGIC INSIGHTS
  • 1.5. WHO ARE THE KEY PLAYERS IN THE MARKET?

SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE

2. MARKET INTRODUCTION

  • 2.1. DEFINITION
  • 2.2. REPORT SEGMENTATION & SCOPE
  • 2.3. REGIONAL & COUNTRY LEVEL COVERAGE
  • 2.4. WHY YOU NEED THIS REPORT?

3. RESEARCH METHODOLOGY

  • 3.1. RESEARCH PROCESS
  • 3.2. SECONDARY RESEARCH
    • 3.2.1. DATA MINING & CONDENSATION
    • 3.2.2. SOURCES (ASSOCIATIONS, ORGANIZATIONS, MAGAZINES, PAID DATABASES)
  • 3.3. PRIMARY RESEARCH
    • 3.3.1. SAMPLE SIZE (DEMAND-SUPPLY, COMPANY TYPE, DESIGNATIONS, REGION)
    • 3.3.2. SOURCES
  • 3.4. FACTORIAL ANALYSIS & APPROACH SETTING
  • 3.5. ESTIMATION & FORECAST MODELS
  • 3.6. PRICING BASKETS
  • 3.7. ANALYST HOURS & TEAM

SECTION III: QUALITATIVE ANALYSIS

4. MARKET DYNAMICS

  • 4.1. INTRODUCTION
  • 4.2. GROWTH PARAMETERS MAPPED - DRIVERS
    • 4.2.1. GROWING AGING POPULATION
    • 4.2.2. IMPROVED IDENTIFICATION AND DIAGNOSIS
    • 4.2.3. INCREASING DEMAND FOR TECHNOLOGICALLY ADVANCED TREATMENT
  • 4.3. WHAT ARE THE CHALLENGES FACED BY INDUSTRY PARTICIPANTS?
    • 4.3.1. HIGH COST OF TREATMENT
    • 4.3.2. THREAT TO DATA SECURITY &STRICT REGULATORY COMPLIANCE
  • 4.4. OPPORTUNITIES
    • 4.4.1. COLLABORATION WITH PHARMACEUTICAL COMPANIES AND ACADEMIC INSTITUTIONS
    • 4.4.2. OPPORTUNITY
    • 4.4.3. OPPORTUNITY

5. MARKET FACTOR ANALYSIS

  • 5.1. VALUE CHAIN ANALYSIS
    • 5.1.1. R&D AND DESIGNING
    • 5.1.2. MANUFACTURING
    • 5.1.3. DISTRIBUTION & SALES
    • 5.1.4. POST SALES SERVICES
  • 5.2. PORTER'S FIVE FORCES MODEL
    • 5.2.1. BARGAINING POWER OF SUPPLIERS
    • 5.2.2. BARGAINING POWER OF BUYERS
    • 5.2.3. THREAT OF NEW ENTRANTS
    • 5.2.4. THREAT OF SUBSTITUTES
    • 5.2.5. INTENSITY OF RIVALRY
  • 5.3. COVID-19 IMPACT ANALYSIS
    • 5.3.1. IMPACT ON R&D
    • 5.3.2. IMPACT ON PRICING
    • 5.3.3. IMPACT ON REGIONS

SECTION IV: QUANTITATIVE ANALYSIS

6. GLOBAL DELIRIUM MARKET, BY TYPE (USD MILLION)

  • 6.1. INTRODUCTION
  • 6.2. HYPERACTIVE
    • 6.2.1. GLOBAL DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY HYPERACTIVE,-2030
  • 6.3. HYPOACTIVE
    • 6.3.1. GLOBAL DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY HYPOACTIVE,-2030
  • 6.4. MIXED
    • 6.4.1. GLOBAL DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY MIXED,-2030

7. GLOBAL DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT (USD MILLION)

  • 7.1. INTRODUCTION
  • 7.2. DIAGNOSIS
    • 7.2.1. GLOBAL DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS,-2030
    • 7.2.2. LABORATORY TESTS
    • 7.2.3. PHYSICAL EXAMINATION
    • 7.2.4. IMAGING TEST
  • 7.3. TREATMENT
    • 7.3.1. GLOBAL DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TREATMENT,-2030
    • 7.3.2. ANTIPSYCHOTICS
    • 7.3.3. SUPPORTIVE CARE

8. GLOBAL DELIRIUM MARKET, BY END USER (USD MILLION)

  • 8.1. INTRODUCTION
  • 8.2. HOSPITALS
    • 8.2.1. GLOBAL DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY HOSPITALS,-2030
  • 8.3. SPECIALITY CARE
    • 8.3.1. GLOBAL DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY SPECIALITY CARE,-2030
  • 8.4. RESEARCH CENTERS
    • 8.4.1. GLOBAL DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY RESEARCH CENTERS,-2030

9. GLOBAL DELIRIUM MARKET, BY REGION (USD MILLION)

  • 9.1. INTRODUCTION
  • 9.2. NORTH AMERICA
    • 9.2.1. NORTH AMERICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY COUNTRY,-2030
    • 9.2.2. NORTH AMERICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
    • 9.2.3. NORTH AMERICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
    • 9.2.4. NORTH AMERICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
    • 9.2.5. US
    • 9.2.6. US DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
    • 9.2.7. US DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.2.7.1. US DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
    • 9.2.8. CANADA
      • 9.2.8.1. CANADA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
      • 9.2.8.2. CANADA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.2.8.3. CANADA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
    • 9.2.9. MEXICO
      • 9.2.9.1. MEXICO DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
      • 9.2.9.2. MEXICO DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.2.9.3. MEXICO DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
  • 9.3. EUROPE
      • 9.3.1.1. EUROPE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY COUNTRY,-2030
      • 9.3.1.2. EUROPE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
      • 9.3.1.3. EUROPE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.3.1.4. EUROPE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
    • 9.3.2. GERMANY
      • 9.3.2.1. GERMANY DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
      • 9.3.2.2. GERMANY DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.3.2.3. GERMANY DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
    • 9.3.3. FRANCE
      • 9.3.3.1. FRANCE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
      • 9.3.3.2. FRANCE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.3.3.3. FRANCE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
    • 9.3.4. UK
      • 9.3.4.1. UK DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
      • 9.3.4.2. UK DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.3.4.3. UK DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
    • 9.3.5. SPAIN
      • 9.3.5.1. SPAIN DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
      • 9.3.5.2. SPAIN DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.3.5.3. SPAIN DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
    • 9.3.6. ITALY
      • 9.3.6.1. ITALY DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
      • 9.3.6.2. ITALY DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.3.6.3. ITALY DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
    • 9.3.7. REST OF EUROPE
      • 9.3.7.1. REST OF EUROPE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
      • 9.3.7.2. REST OF EUROPE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.3.7.3. REST OF EUROPE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
  • 9.4. ASIA-PACIFIC
    • 9.4.1. ASIA PACIFIC DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY COUNTRY,-2030
    • 9.4.2. ASIA PACIFIC DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
    • 9.4.3. ASIA PACIFIC DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
    • 9.4.4. ASIA PACIFIC DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
    • 9.4.5. CHINA
      • 9.4.5.1. CHINA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
      • 9.4.5.2. CHINA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.4.5.3. CHINA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
    • 9.4.6. INDIA
      • 9.4.6.1. INDIA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
      • 9.4.6.2. INDIA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.4.6.3. INDIA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
    • 9.4.7. JAPAN
      • 9.4.7.1. JAPAN DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
      • 9.4.7.2. JAPAN DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.4.7.3. JAPAN DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
    • 9.4.8. SOUTH KOREA
      • 9.4.8.1. SOUTH KOREA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
      • 9.4.8.2. SOUTH KOREA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.4.8.3. SOUTH KOREA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
    • 9.4.9. AUSTRALIA
      • 9.4.9.1. AUSTRALIA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
      • 9.4.9.2. AUSTRALIA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.4.9.3. AUSTRALIA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
    • 9.4.10. REST OF ASIA-PACIFIC
      • 9.4.10.1. REST OF ASIA-PACIFIC DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
      • 9.4.10.2. REST OF ASIA-PACIFIC DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.4.10.3. REST OF ASIA-PACIFIC DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
  • 9.5. REST OF THE WORLD
    • 9.5.1. MIDDLE EAST & AFRICA
      • 9.5.1.1. MIDDLE EAST AND AFRICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
      • 9.5.1.2. MIDDLE EAST AND AFRICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.5.1.3. MIDDLE EAST AND AFRICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
    • 9.5.2. LATIN AMERICA
      • 9.5.2.1. LATIN AMERICA AND AFRICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
      • 9.5.2.2. LATIN AMERICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.5.2.3. LATIN AMERICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030

SECTION V: COMPETITIVE ANALYSIS

10. COMPETITIVE LANDSCAPE

  • 10.1. INTRODUCTION
  • 10.2. COMPETITION DASHBOARD
  • 10.3. COMPANY MARKET SHARE ANALYSIS,-23 (%)
  • 10.4. WHO ARE THE MARKET DISRUPTORS & INNOVATORS?
  • 10.5. WHAT STRATEGIES ARE BEING ADOPTED BY MARKET LEADERS?
  • 10.6. COMPETITIVE BENCHMARKING
  • 10.7. THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL DELIRIUM MARKET
  • 10.8. LIST OF KEY PLAYERS, BY REGION
  • 10.9. PUBLIC PLAYERS STOCK SUMMARY
  • 10.10. COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL
  • 10.11. KEY DEVELOPMENTS & GROWTH STRATEGIES
    • 10.11.1. NEW TYPE LAUNCH/SERVICE DEPLOYMENT
    • 10.11.2. MERGER & ACQUISITION
    • 10.11.3. JOINT VENTURES

11. COMPANY PROFILES

  • 11.1. OTSUKA PHARMACEUTICAL CO., LTD
    • 11.1.1. COMPANY OVERVIEW
    • 11.1.2. FINANCIAL OVERVIEW
    • 11.1.3. PRODUCT OFFERED
    • 11.1.4. KEY DEVELOPMENTS
    • 11.1.5. SWOT ANALYSIS
    • 11.1.6. KEY STRATEGIES
  • 11.2. MYLAN N.V
    • 11.2.1. COMPANY OVERVIEW
    • 11.2.2. FINANCIAL OVERVIEW
    • 11.2.3. PRODUCT OFFERED
    • 11.2.4. KEY DEVELOPMENTS
    • 11.2.5. SWOT ANALYSIS
    • 11.2.6. KEY STRATEGIES
  • 11.3. TEVA PHARMACEUTICAL INDUSTRIES LTD
    • 11.3.1. COMPANY OVERVIEW
    • 11.3.2. FINANCIAL OVERVIEW
    • 11.3.3. PRODUCT OFFERED
    • 11.3.4. KEY DEVELOPMENTS
    • 11.3.5. SWOT ANALYSIS
    • 11.3.6. KEY STRATEGIES
  • 11.4. ZYDUS GROUP
    • 11.4.1. COMPANY OVERVIEW
    • 11.4.2. FINANCIAL OVERVIEW
    • 11.4.3. PRODUCT OFFERED
    • 11.4.4. KEY DEVELOPMENTS
    • 11.4.5. SWOT ANALYSIS
    • 11.4.6. KEY STRATEGIES
  • 11.5. GLENMARK PHARMACEUTICALS LTD
    • 11.5.1. COMPANY OVERVIEW
    • 11.5.2. FINANCIAL OVERVIEW
    • 11.5.3. PRODUCT OFFERED
    • 11.5.4. KEY DEVELOPMENTS
    • 11.5.5. SWOT ANALYSIS
    • 11.5.6. KEY STRATEGIES
  • 11.6. PFIZER
    • 11.6.1. COMPANY OVERVIEW
    • 11.6.2. FINANCIAL OVERVIEW
    • 11.6.3. PRODUCT OFFERED
    • 11.6.4. KEY DEVELOPMENTS
    • 11.6.5. SWOT ANALYSIS
    • 11.6.6. KEY STRATEGIES
  • 11.7. MYLAN N.V
    • 11.7.1. COMPANY OVERVIEW
    • 11.7.2. FINANCIAL OVERVIEW
    • 11.7.3. PRODUCT OFFERED
    • 11.7.4. KEY DEVELOPMENTS
    • 11.7.5. SWOT ANALYSIS
    • 11.7.6. KEY STRATEGIES
  • 11.8. TEVA PHARMACEUTICAL INDUSTRIES LTD
    • 11.8.1. COMPANY OVERVIEW
    • 11.8.2. FINANCIAL OVERVIEW
    • 11.8.3. PRODUCT OFFERED
    • 11.8.4. KEY DEVELOPMENTS
    • 11.8.5. SWOT ANALYSIS
    • 11.8.6. KEY STRATEGIES
  • 11.9. GLENMARK PHARMACEUTICALS LTD
    • 11.9.1. COMPANY OVERVIEW
    • 11.9.2. FINANCIAL OVERVIEW
    • 11.9.3. PRODUCT OFFERED
    • 11.9.4. KEY DEVELOPMENTS
    • 11.9.5. SWOT ANALYSIS
    • 11.9.6. KEY STRATEGIES
  • 11.10. NOVARTIS AG
    • 11.10.1. COMPANY OVERVIEW
    • 11.10.2. FINANCIAL OVERVIEW
    • 11.10.3. PRODUCT OFFERED
    • 11.10.4. KEY DEVELOPMENTS
    • 11.10.5. SWOT ANALYSIS
    • 11.10.6. KEY STRATEGIES

12. RECOMMENDATIONS & EXPERT INSIGHTS

  • 12.1. WHAT IS THE SHORT-TERM VS LONG-TERM OUTLOOK FOR DELIRIUM MARKET?
  • 12.2. WHO ARE THE PLAYERS TO LOOK OUT FOR?
  • 12.3. WHAT WILL THE PRODUCT MIX LOOK IN COMING YEARS?

13. MRFR OFFERINGS & TEAM

  • 13.1. CITATIONS & MEDIA
  • 13.2. OUR REGIONAL REPRESENTATIVES
  • 13.3. RELATED REPORTS
  • 13.4. OUR DOMAIN COVERAGE

LIST OF TABLES

  • TABLE 1. LIST OF ASSUMPTIONS
  • TABLE 2. GLOBAL DELIRIUM MARKET ESTIMATES & FORECAST, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 3. GLOBAL DELIRIUM MARKET FOR HYPERACTIVE MARKET ESTIMATES & FORECAST, BY REGION, 2019-2030 (USD MILLION)
  • TABLE 4. GLOBAL DELIRIUM MARKET FOR HYPOACTIVE MARKET ESTIMATES & FORECAST, BY REGION, 2019-2030 (USD MILLION)
  • TABLE 5. GLOBAL DELIRIUM MARKET FOR MIXED MARKET ESTIMATES & FORECAST, BY REGION, 2019-2030 (USD MILLION)
  • TABLE 6. GLOBAL DELIRIUM MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 7. GLOBAL DELIRIUM MARKET FOR DIAGNOSIS MARKET ESTIMATES & FORECAST, BY REGION, 2019-2030 (USD MILLION)
  • TABLE 8. GLOBAL DELIRIUM MARKET FOR TREATMENT MARKET ESTIMATES & FORECAST, BY REGION, 2019-2030 (USD MILLION)
  • TABLE 9. GLOBAL DELIRIUM MARKET ESTIMATES & FORECAST, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 10. GLOBAL DELIRIUM MARKET FOR HOSPITALS MARKET ESTIMATES & FORECAST, BY REGION, 2019-2030 (USD MILLION)
  • TABLE 11. GLOBAL DELIRIUM MARKET FOR SPECIALITY CARE MARKET ESTIMATES & FORECAST, BY REGION, 2019-2030 (USD MILLION)
  • TABLE 12. GLOBAL DELIRIUM MARKET FOR RESEARCH CENTERS MARKET ESTIMATES & FORECAST, BY REGION, 2019-2030 (USD MILLION)
  • TABLE 13. GLOBAL DELIRIUM MARKET MARKET, BY REGION, 2019-2030 (USD MILLION)
  • TABLE 14. NORTH AMERICA: DELIRIUM MARKET, BY COUNTRY, 2019-2030 (USD MILLION)
  • TABLE 15. NORTH AMERICA: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 16. NORTH AMERICA: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT 2019-2030 (USD MILLION)
  • TABLE 17. NORTH AMERICA: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION
  • TABLE 18. U.S.: DELIRIUM MARKET, BY ACCESS, 2019-2030 (USD MILLION)
  • TABLE 19. U.S.: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 20. CANADA: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 21. CANADA: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 22. CANADA.: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 23. MEXICO: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 24. MEXICO: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 25. MEXICO.: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 26. EUROPE: DELIRIUM MARKET, BY COUNTRY, 2019-2030 (USD MILLION)
  • TABLE 27. EUROPE: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 28. EUROPE: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 29. EUROPE: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 30. GERMANY: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 31. GERMANY: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 32. GERMANY: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 33. FRANCE: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 34. FRANCE: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 35. FRANCE: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 36. UK: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 37. UK: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 38. UK: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 39. SPAIN: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 40. SPAIN: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 41. SPAIN: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 42. ITALY: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 43. ITALY: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 44. ITALY: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 45. REST OF EUROPE: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 46. REST OF EUROPE: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 47. REST OF EUROPE: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 48. ASIA PACIFIC: DELIRIUM MARKET, BY COUNTRY, 2019-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 52. CHINA: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 53. CHINA: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 54. CHINA: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 55. INDIA: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 56. INDIA: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 57. INDIA: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 58. JAPAN: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 59. JAPAN: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 60. JAPAN: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 61. SOUTH KOREA: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 62. SOUTH KOREA: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 63. SOUTH KOREA: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 67. REST OF ASIA- PACIFIC: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 68. REST OF ASIA- PACIFIC: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 69. REST OF ASIA- PACIFIC: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 70. REST OF THE WORLD: DELIRIUM MARKET, BY COUNTRY, 2019-2030 (USD MILLION)
  • TABLE 71. REST OF THE WORLD: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 72. REST OF THE WORLD: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 73. REST OF THE WORLD: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 74. MIDDLE EAST AND AFRICA: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 75. MIDDLE EAST AND AFRICA: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 76. MIDDLE EAST AND AFRICA: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 77. LATIN AMERICA: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 78. LATIN AMERICA: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 79. LATIN AMERICA: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION

LIST OF FIGURES

  • FIGURE 1. MARKET SYNOPSIS
  • FIGURE 2. RESEARCH PROCESS OF MRFR
  • TABLE 80. DROC ANALYSIS OF GLOBAL DELIRIUM MARKET, 2019-2030
  • FIGURE 3. DRIVERS IMPACT ANALYSIS: GLOBAL DELIRIUM MARKET MARKET
  • FIGURE 4. RESTRAINTS IMPACT ANALYSIS: GLOBAL DELIRIUM MARKET MARKET
  • FIGURE 5. SUPPLY /VALUE CHAIN: ANALYSIS: GLOBAL DELIRIUM MARKET
  • FIGURE 6. MARKET ATTRACTIVENESS ANALYSIS: GLOBAL DELIRIUM MARKET
  • FIGURE 7. GLOBAL DELIRIUM MARKET ANALYSIS BY TYPE
  • FIGURE 8. GLOBAL DELIRIUM MARKET ANALYSIS BY DIAGNOSIS AND TREATMENT
  • FIGURE 9. GLOBAL DELIRIUM MARKET ANALYSIS BY END USER
  • FIGURE 10. GLOBAL DELIRIUM MARKET ANALYSIS BY REGION
  • FIGURE 11. GLOBAL VASCULAR CLOSURE HYPERACTIVE MARKET: MARKET STRUCTURE
  • FIGURE 12. NORTH AMERICA DELIRIUM MARKET & MARKET SHARE BY COUNTRY (2019 VS 2030)
  • FIGURE 13. EUROPE MARKET SIZE & MARKET SHARE BY COUNTRY (2019 VS 2030)
  • FIGURE 14. ASIA-PACIFIC & MARKET SHARE BY COUNTRY (2019 VS 2030)
  • FIGURE 15. REST OF THE WORLD MARKET SIZE & MARKET SHARE BY COUNTRY (2019 VS 2030)